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Abstract
Background: Two thousand fifteen has been a winning year for Drug Eluting Stents (DES). Increase in the number
of patients with cardiovascular diseases treated by Percutaneous Coronary Intervention (PCI) has resulted to a high
demand for second generation DES. This current analysis aimed to compare the different types of Stent Thrombosis
(ST) associated with Zotarolimus Eluting Stents (ZES) versus Everolimus Eluting Stents (EES) at 1 year follow up.
Methods: Electronic databases were searched for studies comparing ZES with EES. Different types of ST reported at
1 year follow up were considered as the primary endpoints in this analysis. Odds Ratios (OR) with 95% Confidence
Intervals (CIs) were used as the statistical parameters and the pooled analyses were carried out by the RevMan 5 · 3
software.
Results: A total number of 10,512 patients were included in this analysis. No significant difference in any definite ST,
acute definite ST, subacute definite ST, and late definite ST were observed between ZES and EES, at 1 year follow up with
OR: 1.70, 95% CI: 0.92 – 3.16; P = 0.09, OR: 3.44, 95% CI: 0.82 – 14.43; P = 0.09, OR: 1.13, 95% CI: 0.43 – 2.95; P = 0.80 and OR:
2.39, 95% CI: 0.83 – 6.85; P = 0.11 respectively. Moreover, any definite or probable ST and definite/probable/possible ST
were also not significantly different with OR: 1.39, 95% CI: 0.89 – 2.17; P = 0.15 and OR: 1.19, 95% CI: 0.84 – 1.70; P = 0.33
respectively. In addition, any probable ST, acute probable ST, late probable ST and possible ST were also not significantly
different at 1 year follow up with OR: 1.11, 95% CI: 0.60 – 2.05; P = 0.75, OR: 0.53, 95% CI: 0.12 – 2.40; P = 0.41, OR: 1.67, 95%
CI: 0.35 – 7.86; P = 0.52 and OR: 1.08, 95% CI: 0.64 – 1.82; P = 0.78 respectively.
Conclusion: At 1 year follow up, ZES were not associated with significantly lower or higher definite and probable ST
compared to EES. In addition, no significant difference was observed in acute, subacute and late definite or probable ST.
However, further trials are recommended to assess the effects of these second-generation DES during the long-term.
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Background
Two thousand fifteen has been a winning year for Drug
Eluting Stents (DES). Increase in the number of patients
with cardiovascular diseases treated by Percutaneous
Coronary Intervention (PCI) has resulted to a higher de-
mand for second generation DES. Even if DES won the
battle in terms of repeated revascularization when com-
pared to Bare Metal Stents (BMS) [1], they also had
short comings related mostly to long-term Stent Throm-
bosis (ST). Previously, several meta-analyses were car-
ried out to compare ST associated with Sirolimus
Eluting Stents (SES) and Paclitaxel Eluting Stents (PES),
whereby SES were non-inferior to PES [2]. Later on,
when Everolimus Eluting Stents (EES) were compared
to non-EE DES, the formers were associated with a
significantly lower rate of ST [3]. However, ST in pa-
tients treated with Zotarolimus Eluting Stents (ZES)
and EES have seldom been analyzed using a large
number of randomized patients. Previously published
meta-analyses which focused mainly on the general
adverse clinical outcomes associated with ZES and
EES, did not specifically focus on the different types
of ST following PCI [4, 5]. Hence, this current ana-
lysis aimed to compare ST associated with ZES versus
EES at 1 year follow up, using a large number of pa-
tients extracted from randomized trials.
Methods
Data sources and search strategies
The Cochrane Library, MEDLINE or PubMed database
of medical research articles, and EMBASE were searched
by two authors (PKB and CMY), for English publications
comparing ZES with EES using the words or phrase
‘zotarolimus eluting stents and everolimus eluting
stents’. To widen this search strategy, the word ‘percu-
taneous coronary intervention’ and the abbreviations
‘ZES, EES and PCI’ were also used. Reference lists of
suitable articles were also searched for relevant trials.
Inclusion and exclusion criteria
Studies were included if:
(a)They were Randomized Controlled Trials (RCTs)
which compared ZES with EES in patients who
underwent PCI.
(b)They reported ST and other adverse outcomes as
their clinical endpoints.
(c)They had a follow up period of 1 year.
Table 1 Primary outcomes reported
Trial name Primary outcomes and types of ST reported
DUTCH PEERS [17] Any definite ST (0-360 d), acute definite ST (0-1 d),
subacute definite ST (2-30 d), late definite ST (31-360
d), any definite or probable ST (0-360 d), any possible
ST (0-360 d), any definite/probable/possible (0-360 d)
HOST-ASSURE [18] Definite or probable ST, acute definite or probable
ST, subacute definite or probable ST, early definite
or probable ST, late definite or probable ST, any
definite ST, acute definite ST, subacute definite ST,
early definite ST, late definite ST, probable ST, acute
probable ST, subacute probable ST, early probable
ST, late probable ST, possible ST, acute possible ST,
subacute possible ST, early possible ST, late
possible ST
Lin 2015 [15] ST
Mehilli 2013 [16] Definite ST, probable ST
RESOLUTE [19] Any definite ST (0-360 d), acute definite ST (0-1 d),
subacute definite ST (2-30 d), late definite ST (31-
360 d), any probable ST (0-360 d), acute probable
ST (0-1 d), subacute probable ST (2-30 d), late
probable ST (31-360 d), possible ST, definite or
probable ST, definite/probable/possible ST
TWENTE [20] Any definite ST (0-360 d), acute definite ST (0-1 d),
subacute definite ST (2-30 d), late definite ST (31-
360 d), any probable ST (0-360 d), acute probable
ST (0-1 d), subacute probable ST (2-30 d), late
probable ST (31-360 d), possible ST, definite or
probable ST, definite/probable/possible ST
Abbreviations: ST stent thrombosis
Table 2 Secondary outcomes reported
Trial name Other adverse outcomes Follow up
period
DAPT use
DUTCH PEERS [17] TVF, all-cause death, cardiac
death, TVMI, any TVR, clinic-
ally indicated TVR, clinically
indicated TLR, TLF, MACEs,
patient-oriented composite
endpoint
12 months 1 year





12 months 1 year
Lin 2015 [15] Adverse cardiac events,
all-cause death, cardiac
death, MI
15 months 1 year
Mehilli 2013 [16] All-cause death, MI, stroke,
TLR, patient-oriented
composite endpoint
12 months 1 year
RESOLUTE [19] TLR, all-cause death, car-
diac death, TVMI, clinically
indicated TLR, MI, clinic-
ally indicated TVR, MACEs,
patient-oriented compos-
ite endpoint, TVF
12 months 6 months
to 1 year
TWENTE [20] TVF, all-cause death, car-
diac death, TVMI, clinically
indicated TVR, TLF, clinic-
ally indicated TLR, MACEs,
patient-oriented compos-
ite endpoint
12 months 1 year
TVF target vessel failure, TVMI target vessel related myocardial infarction, TVR
target vessel revascularization, TLF target lesion failure, MACEs major adverse
cardiac events, CVA cardiovascular accident, TVF target vessel failure, MI
myocardial infarction, DAPT dual antiplatelet therapy
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Studies were excluded if:
(a)They were non-RCTs (observational studies, case
studies, meta-analyses or letters to editors).
(b)They did not compare ZES with EES.
(c)They did not report ST or other adverse outcomes
as their clinical endpoints.
(d)They were associated with the same trial.
(e)They were repeated trials or duplicates.
Outcomes and follow up
The primary outcomes analyzed included ST defined by






(f )Acute probable ST;
(g)Subacute probable ST;
(h)Late probable ST;
(i) Any definite or probable ST;
(j) Possible ST;
(k)Definite/probable or possible ST.
The secondary outcomes analyzed included:
(a)All-cause death;
(b)Cardiac death;
(c)Major Adverse Cardiac Events (MACEs) which were
defined as a composite of all cause death,
Myocardial Infarction (MI), emergent coronary
artery bypass surgery (CABG) and clinically-
indicated target lesion revascularization;
(d)Stroke;
(e)Patient-oriented composite endpoint consisting of
all-cause mortality, MI and any coronary
revascularization;
(f )MI;
(g)Target Vessel Revascularization (TVR);
(h)Target Lesion Revascularization (TLR);
(i) Target Vessel Failure (TVF);
(j) Target Lesion Failure (TLF).
These outcomes were followed for 1 year after PCI.
Table 1 summarizes the primary outcomes reported in
each trial whereas Table 2 lists the secondary outcomes
with their corresponding follow up periods following PCI.
Table 3 Bias risk assessment according to the cochrane collaboration
Components assessed DUTCH PEERS [17] HOST-ASSURE [18] Lin2015 [15] Mehilli 2013 [16] RESOLUTE [19] TWENTE [20]
1 2 2 2 2 2 2
2 2 2 1 2 2 2
3 1 1 1 1 2 1
4 2 1 1 1 2 2
5 1 1 1 1 1 1
6 1 1 1 1 1 1
Total score 9 8 7 8 10 9
Bias grade B B C B A B
The six components recommended by the Cochrane Collaborations to assess bias risk
1: Sequence generation
2: Allocation sequence concealment
3: Blinding of participants and personnel
4: Blinding of outcome assessment
5: Incomplete outcome data
6: Selective outcome reporting and other potential bias
Fig. 1 Flow diagram showing the study selection
Bundhun et al. BMC Cardiovascular Disorders  (2017) 17:84 Page 3 of 12
Data extraction and review
The same two authors (PKB and CMY) who were in-
volved in the search process, carefully reviewed the trials
and assessed their methodological quality. The bias
risk was assessed with reference to the Cochrane
Collaboration [7]. The six components assessing the
bias risk were taken into consideration and a score
ranging from 0 to 2 was allocated to each compo-
nent (low risk, unclear or high risk of bias). A max-
imum total score of 12 implied a very low risk of
bias. The methodological information which were
obtained from these trials were used to assess the
bias risk, and was strictly dependent on what the au-
thors have observed. Any feature which was missed
during this assessment was ignored (an up and down
of the score was possible). Grades were also allo-
cated whereby a grade A implied a very low risk of
bias whereas a grade E represented a very high risk
of bias. Table 3 lists the scores and grades allocated
to each eligible trial.
Moreover, information and data concerning the types
of study reported, the patients’ enrollment period, the
total number of patients treated by ZES and EES re-
spectively, the reported primary and secondary out-
comes, the follow up periods, the number of events that
occurred in the study and the control groups, and infor-
mation regarding the baseline features of the patients in-
volved in this analysis were systematically extracted. Any
disagreement or confusion concerning the eligibility of
trials, or concerning the inclusion of certain data were
discussed between these two authors, however, if a con-
sensus could not be reached, disagreement was finally
resolved by the third author (WQH).
Statistical analysis
The Preferred Reporting Items for Systematic Reviews
and Meta-Analyses [8] statement was considered rele-
vant for this analysis which involved only randomized
trials. Assessment of heterogeneity during the subgroup
analysis was strictly dependent on the Cochrane Q-
statistic test and the I2 statistic test. A P value of ≤ 0.05
was considered statistically significant. Moreover, an I2
value of 0% indicated no or very low heterogeneity, and
an increasing percentage of I2 implied an increasing het-
erogeneity. In addition, a fixed effects model (I2 < 50%)
and a random effects model (I2 > 50%) depending on
the value of I2 obtained. Publication bias was assessed
by visually observing funnel plots. Odds Ratios (OR)
with 95% Confidence Intervals (CIs) were calculated
and the subgroup analyses were carried out by the
RevMan 5·3 software. All authors had full access to
the trials and their data. Ethical or board review




Four hundred and twenty-eight (428) studies were iden-
tified from the electronic databases. Three hundred and
forty-five studies were eliminated through abstracts and
Table 4 General features of the trials included
Trials Patients’ enrollment Type of study No of patients in ZES group (n) No of patients in EES group (n)
DUTCH PEERS [17] 2010 - 2012 RCT 905 905
HOST-ASSURE [18] 2010 - 2011 RCT 1252 2503
Lin 2015 [15] 2008 - 2013 RCT 333 333
Mehilli 2013 [16] 2007 - 2011 RCT 324 326
RESOLUTE [19] 2008 - 2008 RCT 1121 1128
TWENTE [20] 2008 - 2010 RCT 695 692
Total no of patients (n) 4630 5887
Abbreviations: ZES zotarolimus eluting stents, EES everolimus eluting stents, RCT randomized controlled trials
Table 5 Baseline features of the trials included
Trial name Mean age Males (%) Ht (%) Ds (%) Cs (%) DM (%)
ZES/EES ZES/EES ZES/EES ZES/EES ZES/EES ZES/EES
DUTCH PEERS [17] 64.0/65.0 73.0/73.0 55.0/53.0 46.0/48.0 24.0/26.0 18.0/17.0
HOST-ASSURE [18] 63.5/63.1 65.6/69.8 68.1/68.2 65.7/64.0 29.5/32.9 32.0/31.8
Lin 2015 [15] 63.0/65.5 72.8/73.4 71.9/69.6 59.3/57.4 64.8/51.4 25.5/25.2
Mehilli 2013 [16] 69.4/70.2 72.8/77.3 68.2/69.9 68.8/75.8 14.8/13.2 28.4/28.5
RESOLUTE [19] 64.4/64.2 76.7/77.2 71.1/71.3 63.9/67.7 26.5/26.5 23.5/23.4
TWENTE [20] 63.9/64.5 72.5/72.5 55.4/55.8 57.0/61.4 25.3/23.6 22.7/20.6
Abbreviations: Ht hypertension, Ds dyslipidemia, Cs current smoker, DM diabetes mellitus, ZES zotarolimus eluting stents, EES everolimus eluting stents
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titles since they did not address any issue related to the
idea of this research. A further 32 articles were eliminated
since they replicated themselves. Fifty-one (51) full-text
articles were assessed for eligibility. Seventeen (17) more
articles were eliminated since they were meta-analyses (2),
letters to editors (3) or they were associated with the same
trial (12). Thirty-four (34) studies met most of the inclu-
sion and exclusion criteria of this meta-analysis. However,
since it involved only randomized trials, a further 28 stud-
ies were excluded because they were observational studies.
Finally, 6 trials were included in this analysis (Fig. 1).
General features of the trials included in this study
Table 4 shows the main features of the trials which were
considered fully eligible for this analysis.
A total number of 10,512 patients (4630 patients were
treated by ZES and 5887 patients were treated by EES)
were included in this analysis. Patients were enrolled
from the year 2007 to the year 2013.
Baseline features of the patients involved
The baseline features of the participants have been sum-
marized in Table 5.
According to Table 5, no significant difference was ob-
served in the baseline features among patients who were
treated by ZES and EES respectively.
Stent Thrombosis associated with ZES and EES at 1 year
follow up
Results of this analysis has been summarized in
Table 6.
No significant difference was observed between ZES
and EES when analyzing any definite ST, acute definite
ST, subacute definite ST, and late definite ST observed
at 1 year follow up with OR: 1.70, 95% CI: 0.92 – 3.16;
P = 0.09, OR: 3.44, 95% CI: 0.82 – 14.43; P = 0.09, OR:
1.13, 95% CI: 0.43 – 2.95; P = 0.80 and OR: 2.39, 95%
CI: 0.83 – 6.85; P = 0.11 respectively when a fixed effects
model was used. Another analysis was carried out using
a random effects model to analyze the subgroup ‘any
definite ST’. However, similarly, no significant difference
was observed with OR: 1.53, 95% CI: 0.56 – 4.17; P =
0.41. Moreover, any definite or probable ST and definite/
probable/possible ST were also not significant between
these two types of second-generation DES with OR: 1.39,
95% CI: 0.89 – 2.17; P = 0.15 and OR: 1.19, 95% CI: 0.84 –
1.70; P = 0.33 respectively. Results showing definite ST
and its subtypes have been illustrated in Fig. 2.
Any probable ST, acute probable ST, late probable ST
and possible ST were also not significantly different with
OR: 1.11, 95% CI: 0.60 – 2.05; P = 0.75, OR: 0.53, 95%
CI: 0.12 – 2.40; P = 0.41, OR: 1.67, 95% CI: 0.35 – 7.86;
P = 0.52 and OR: 1.08, 95% CI: 0.64 – 1.82; P = 0.78 re-
spectively at 1 year following PCI (Fig. 3). Since a high
level of heterogeneity was observed when analyzing sub-
acute probable ST, a random effects model was used to
analyze this subgroup which showed comparable result
between these two types of second-generation DES with
OR: 0.98, 95% CI: 0.14 – 6.63; P = 0.98 (Fig. 4).
Other adverse clinical outcomes associated with ZES and
EES at 1 year follow up
Although this analysis assessed the different types of
ST manifested between ZES and EES, other adverse
clinical outcomes were also analyzed. The current
results showed a comparable rate of all-cause death
and cardiac death between ZES and EES with OR:
0.95, 95% CI: 0.73 – 1.22; P = 0.67 and OR: 1.02,
95% CI: 0.72 – 1.44; P = 0.93 respectively. MACEs,
stroke, patient-oriented composite endpoints, and MI
were also similarly observed between ZES and EES
with OR: 1.05, 95% CI: 0.87 – 1.28; P = 0.61, OR:
1.03, 95% CI: 0.48 – 2.18; P = 0.95, OR: 1.03, 95%
CI: 0.89 – 1.18; P = 0.72 and OR: 1.21, 95% CI: 0.94
– 1.55; P = 0.14 respectively (Fig. 5).
This analysis showed a similar rate of TVR, TLR, TVF
and TLF reported between ZES and EES with OR: 1.06,
95% CI: 0.83 – 1.35; P = 0.66, OR: 1.19, 95% CI: 0.93 –
1.53; P = 0.16, OR: 1.02, 95% CI: 0.85 – 1.21; P = 0.87 and
OR: 1.08, 95% CI: 0.89 – 1.30; P = 0.44 respectively (Fig. 6).
Sensitivity analysis
Sensitivity analysis was also carried out to find out whether
the results were influenced by any of the trial which was in-
cluded during the subgroup analysis. Trials were excluded
one at a time, and then a new analysis was carried out. This
Table 6 Results of this analysis
Outcomes analyzed No of trials
reporting these
outcomes (n)




Any definite ST 6 1.70 [0.92 – 3.16] 0.09 43
Acute definite ST 4 3.44 [0.82 – 14.43] 0.09 0
Subacute definite ST 4 1.13 [0.43 – 2.95] 0.80 46
Late definite ST 4 2.39 [0.83 – 6.85] 0.11 0
Any probable ST 6 1.11 [0.60 – 2.05] 0.75 20
Acute probable ST 3 0.53 [0.12 – 2.40] 0.41 0
Subacute probable ST 3 0.98 [0.14 – 6.63] 0.98 67
Late probable ST 3 1.67 [0.35 – 7.86] 0.52 0
Any definite or
probable ST
6 1.39 [0.89 – 2.17] 0.15 7
Possible ST 4 1.08 [0.64 – 1.82] 0.78 0
Definite/probable or
possible ST
3 1.19 [0.84 – 1.70] 0.33 0
Abbreviations: OR odds ratios, CI confidence intervals, ST stent thrombosis
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process was repeated with the exclusion of a different trial
each time. Within the subgroup assessing ‘any definite ST’,
excluding trial DUTCH PEERS and HOST ASSURE re-
spectively, showed significant results supporting EES with
OR: 2.44, 95% CI: 1.17 – 5.08; P = 0.02 and OR: 2.05, 95%
CI: 1.04 – 4.04; P = 0.04 respectively. In addition, when trial
DUTCH PEERS was excluded when analyzing late definite
ST, a statistically significant result favoring EES was
obtained with OR: 3.73, 95% CI: 1.02 – 13.59; P = 0.05.
However, the significance approached the cut-off value.
When the same trial was excluded while analyzing ‘any def-
inite or probable ST’, the result again approached statistical
significance with OR: 1.64, 95% CI: 1.00 – 2.68; P = 0.05.
Nevertheless, consistent results were obtained throughout
all the other subgroups. Excluding other trials did not show
any significance compared to the main results obtained.
Fig. 2 Types of Definite Stent Thrombosis associated with ZES versus EES
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Publication bias
After visually assessing the funnel plots, a low publica-
tion bias was observed among most of the subgroups
analyzing the different subtypes of ST and other adverse
clinical outcomes in these patients treated by ZES versus
EES at 1 year follow up. The funnel plots representing
publication bias have been illustrated in Figs. 7 and 8.
Discussion
This analysis aimed to compare ST reported between
ZES and EES in patients with coronary artery disease
during a 1 year follow up. The current results showed
no significant difference in the subgroup analyzing any
definite or probable ST, acute definite or probable ST,
subacute definite or probable ST, late definite or
Fig. 3 Types of Probable Stent Thrombosis associated with ZES versus EES
Fig. 4 Subacute Probable Stent Thrombosis associated with ZES versus EES
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probable ST, possible ST and definite, probable or pos-
sible ST at 1 year follow up. Moreover, among the sub-
groups analyzing MACEs, mortality, MI, stroke, and
repeated revascularization, no significant difference was
observed between ZES and EES.
A meta-analysis [4] comparing the long-term effect of
second generation DES for coronary artery disease, pub-
lished by Li et al, showed ZES and EES to be associated
with a similar efficacy and safety profile. EES did not re-
duce the rate of ST defined by the ARC with OR: 0.83,
95% CI: 0.56 – 0.25; P = 0.37. In contrast to their analysis,
this current analysis involved different subgroups of ST
with a larger number of randomized patients. More-
over, the study by Li et al was limited to the fact that
only two studies reported data on very late ST. An-
other meta-analysis comparing the efficacy and safety
Fig. 5 Adverse clinical outcomes associated with ZES versus EES
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of EES and ZES showed that among randomized tri-
als, ZES and EES were comparable [5]. However,
among data obtained from observational studies, EES
were associated with significantly lower rates of ST
and MACEs compared to ZES. When the data from
randomized trials and observational studies (published
and unpublished studies) were pooled, the results still
showed EES to be associated with a significantly
lower rate of ST compared to ZES. However, a ran-
dom effects model was used during the analysis due
to the presence of a high level of heterogeneity. Be-
cause the meta-analysis published by Gu et al showed
a comparable rate of ST when randomized data were
considered whereas ZES were associated with a sig-
nificantly higher rate of ST compared to EES when
data obtained from observational cohorts were used,
future analysis should include either data obtained only
from randomized trials, or patients obtained only from
observational cohorts without combining them together.
The patient-related and stent-related outcomes from the
multicenter prospective EXCELLENT and RESOLUTE-
Korea Registries which were observational cohorts
consisting of 5054 patients showed a similar rate of defin-
ite and probable ST with ZES and EES at 1 year follow up,
which was also the case for this current analysis involving
data obtained only from randomized trials [9].
Even if this current analysis had a follow up period of
1 year, the study published by Lee et al including Korean
patients undergoing new-generation DES implantation
had a follow up of 33 months (2.8 years) whereby compar-
able clinical outcomes were observed between ZES and
EES [10]. A total number of 9 patients developed ST de-
fined by ARC, however, no significant difference was ob-
served between ZES and EES.
Moreover, results provided by the THCRIC registry also
showed no significant difference in clinical outcomes be-
tween ZES and EES during a 1 year follow up after PCI
[11]. However, ST were not reported in this observational
study. Also, Omar et al showed comparable ST between
EES and ZES; but, when EES were compared to SES, a
lower rate of ST was observed in the EES group whereas
ST between EES and BMS were also similar [12].
When randomized trials were compared, both ZES
and EES were associated with similar rates of ST and
Fig. 6 Repeated Revascularization associated with ZES versus EES
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other adverse clinical outcomes as reported in the
DUTCH PEER trial, and both types of stents could be
recommended in the general population with coronary
artery diseases. The RESOLUTE and TWENTE trials
also reported comparable ST between ZES and EES fur-
ther supporting the results of this current analysis. At
last, even data obtained from a German DES registry,
showed first and second generation DES to be clinically
equivalent at least at 1 year follow-up [13].
A recently published meta-analysis showed Dual Anti-
Platelet Therapy (DAPT) use for less or equal to six
months following PCI with EES or ZES not to cause any
increase or decrease in ST [14]. Even though in this
current analysis, almost all the patients were on dual an-
tiplatelet therapy (DAPT) for 1 year, still no significant
change in ST were observed. However, future trials will
have to show the effect of a longer length of DAPT use
on the occurrence of ST.
Fig. 8 Funnel plots showing publication bias
Fig. 7 Funnel plots showing publication bias
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Novelty
This study is new in the way that it involved a large
number of randomized patients compared to previ-
ously published studies. By excluding patients ob-
tained from observational cohorts, this analysis
involved only good data which resulted in a low level
of heterogeneity during the subgroup analysis. More-
over, previously published meta-analyses did not spe-
cifically focus on ST. This current study analyzed all
possible subtypes of ST including any definite or
probable ST, acute definite or probable ST, subacute
definite or probable ST, late definite or probable ST,
possible ST and definite/probable/possible ST. Fur-
thermore, other adverse clinical outcomes were also
analyzed in details. In addition, bias risk assessment
was carried out, which was not the case in other pre-
viously published meta-analyses.
Limitations
Similar to other studies, this systematic review and
meta-analysis also had limitations. First of all, due to
the limited number of patients analyzed, the results
might be affected. In addition, one trial reported ST
during a follow up of only one month. However, be-
cause the other outcomes reported had a follow up of
1 year, ST reported in that particular trial were
assessed along with the other trials having a follow
up period of 12 months. However, the results were
not affected. Another trial had a follow up period of
15 months. It was included in this analysis and was
expected to partly compensate for the trial which had
a follow up period of one month for ST. Further-
more, a high level of heterogeneity was observed in
the subgroup analyzing subacute probable ST. Even if
this was negligible since this high level of heterogen-
eity was present in only one subgroup, this could also
contribute to the limitations observed in this study.
The fact that different types of patients were in-
cluded, for example a few studies involved only pa-
tients with diabetes mellitus, other studies involved
patients with left main coronary artery disease and so
on, this might have had an influence on the results
obtained. In addition, it might be possible that the
subgroup assessing ‘any definite ST’ was influenced
by trials DUTCH PEER and HOST ASSURE. How-
ever, because ST with several different definitions and
types were included in that particular subgroup,
which might have been the cause for this difference,
this particular result might be ignored. Another limi-
tation could be the fact that this current analysis in-
cluded patients who were implanted with non-
resorbable polymer EES, which are older compared to
recent EES with resorbable polymer which are now-
adays being used.
Conclusion
At 1 year follow up, ZES were not associated with sig-
nificantly lower or higher definite and probable ST com-
pared to EES. In addition, no significant difference was
observed in acute, subacute and late definite or probable
ST. However, further trials are recommended to assess
the effects of these second-generation DES during the
long-term.
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